Comparing the current results to its competitors, Arcutis Biotherapeutics Inc reported Revenue increase in the 2 quarter 2026 by 59.33 % year on year. The sales growth was above Arcutis Biotherapeutics Inc 's competitors' average revenue growth of 11.96 %, achieved in the same quarter.
Arcutis Biotherapeutics Inc 's Comment on Competition and Industry Peers
The company operates in the biotechnology and pharmaceutical industry, which is characterized by rapid changes and intense competition. It competes with major pharmaceutical, specialty pharmaceutical, biotechnology, and generic drug companies, many of which have greater financial, technical, and human resources. Industry consolidation through mergers and acquisitions may concentrate resources among fewer competitors. The company's commercial opportunities may be affected if competitors develop or market products or therapies that offer better symptomatic improvement, lower risk of side effects, or lower cost. Its success depends on developing products that provide lower side effects and/or improved symptomatic relief compared to competing products.
Due to outstanding performance in Overall company, revenue grew by 59.33 % Arcutis Biotherapeutics Inc improved its market share, to approximately 0.1 %.
September 3, 2025
Arcutis Biotherapeutics Inc., a leading dermatology-focused biopharmaceutical company, has recently submitted a supplemental New Drug Application (sNDA) to the United States Food and Drug Administration (FDA) to expand the indication of ZORYVE (roflumilast) cream 0.3%. The aim is to include children ages 2 to 5 years in the treatment for plaque psoriasis, a chronic autoimmune skin condition characterized by red, scaly patches. Regulatory Pursuits and Product ExpansionThe submission of this sNDA is a strategic move reflecting Arcutis commitment to addressing unmet needs in dermatology, particularly for the pediatric population suffering from plaque psoriasis. Currently, treatment options for this age group a...
September 5, 2024
Transformative Advances in Dermatologic Therapies: Arcutis Emerging Leadership in Alopecia Areata and Atopic DermatitisThe landscape of dermatologic treatments is ever-evolving, with significant advancements capturing the attention of clinicians and patients alike. Recently, Arcutis Biotherapeutics has made notable strides in addressing two prevalent skin conditions: alopecia areata and atopic dermatitis. This article synthesizes findings from recent studies and conferences to underscore Arcutis potential impact on the field and the implications for the company s trajectory. Phase 1b Study Enrollment of ARQ-255 for Alopecia Areata Arcutis has completed the enrollment of participants in its Phase 1b study ...
August 28, 2024
: Atopic dermatitis (AD), a prevalent inflammatory skin condition in pediatrics, presents unique challenges in treatment, especially in young children. This article reviews the long-term safety and efficacy results from the INTEGUMENT-OLE study, an open-label trial assessing the effects of roflumilast cream 0.05% in children aged 2 to 5 with mild to moderate atopic dermatitis.Atopic dermatitis is a chronic, relapsing inflammatory skin disorder characterized by pruritus and eczema. The condition significantly impacts the quality of life of affected children and their families. Conventional treatments have limitations, particularly concerning safety and long-term efficacy. Roflumilast cream 0.05% is a phosphod...
June 10, 2024
Arcutis Pharmaceuticals recently unveiled promising data from the INTEGUMENT-OLE long-term open-label study, evaluating the efficacy of investigational once-daily roflumilast cream 0.15% in the treatment of mild to moderate atopic dermatitis (AD) in adults and children as young as six. These findings were presented at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema Conference.1. The INTEGUMENT-OLE Study:In the INTEGUMENT-OLE study, researchers aimed to assess the long-term safety and efficacy of roflumilast cream 0.15% in patients with AD. Roflumilast, a phosphodiesterase type 4 (PDE4) inhibitor, demonstrates anti-inflammatory properties that may alleviate symptoms associated with this chronic infl...
June 5, 2024
Arcutis Unveils New Research at Industry Conference: Implications for Dermatological Conditions : Arcutis Biotherapeutics, Inc., a leading biopharmaceutical company dedicated to providing innovations in the treatment of dermatological conditions, has announced that five abstracts have been accepted for presentation at the Revolutionizing Alopecia Areata, Vitiligo, and Eczema (RAVE) Conference. Scheduled to take place in Chicago from June 8-10, this significant development highlights ongoing advancements in the company s research and its commitment to addressing neglected areas in dermatology. Alopecia areata, vitiligo, and eczema are prevalent dermatological conditions that affect millions globally. These ...
January 14, 2024
Seborrheic dermatitis is a common chronic skin condition characterized by red, itchy, and flaky skin. Topical steroids have long been the primary treatment option, but a significant proportion of patients experience inadequate responses. In a recent subgroup analysis of the STRATUM study, Arcutis announced the successful clearance of seborrheic dermatitis using ZORYVE (Roflumilast) Topical Foam, 0.3% in individuals who previously reported insufficient outcomes with topical steroids. This breakthrough could bring an effective and much-needed therapy to patients suffering from this challenging skin condition.Background:Seborrheic dermatitis affects millions of people worldwide, with a prevalence of up to 5% in...
Publicly Traded Peers of Arcutis Biotherapeutics Inc
Abbvie Inc Share Performance
+11.86%
This Year
Abbvie Inc
Profile
AbbVie Inc operates primarily as a global biopharmaceutical company, focusing on the research, development, manufacturing, and commercialization of advanced therapies and medications in critical areas such as immunology, oncology, neuroscience, and virology. The company aims to improve patient outcomes and address unmet medical needs by leveraging its scientific expertise and capabilities while providing value to stakeholders in the healthcare industry.
Incyte Corporation is a biopharmaceutical company that primarily focuses on the research, development, and commercialization of innovative medicines targeting oncology and serious inflammatory conditions. Their business model emphasizes robust R&D investments to discover potential drug candidates, often engaging in collaborations with other organizations to enhance their development capabilities. Incyte leverages its extensive intellectual property portfolio to protect and maximize the value of its therapeutic advancements in the market.
Johnson & Johnson operates as a multinational healthcare company with a diversified business model that spans pharmaceuticals, medical devices, and consumer health products. By focusing on innovation and strategic acquisitions, the company aims to improve global health and well-being.
Eli Lilly and Company operates as a global pharmaceutical firm that focuses on developing innovative medicines in areas such as diabetes, oncology, and neurodegeneration. Their business model emphasizes research and development, strategic partnerships, and a strong commitment to improving patient outcomes through advanced therapeutics.
MannKind Corporation is a biopharmaceutical company that focuses on the development and commercialization of inhaled therapeutic solutions for patients with diseases such as diabetes and pulmonary arterial hypertension. The company's business model revolves around conducting research and development to create innovative inhalation therapies and gaining regulatory approvals for these treatments. They then market and distribute their products, either directly or through partnerships, to healthcare providers and patients worldwide.
Sources:
Arcutis Biotherapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Arcutis Biotherapeutics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
